We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00586898
First Posted: January 7, 2008
Last Update Posted: March 25, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
Results First Submitted: December 16, 2015  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Prostate
Cancer
Hormonal Cycling
Interventions: Drug: GnRH
Drug: Ketoconazole
Drug: Bicalutamide
Drug: Testosterone transdermal gel
Drug: Estrogen transdermal patch

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
All Participants Rapid Hormonal Cycling as Treatment for Patients with Prostate Cancer

Participant Flow:   Overall Study
    All Participants
STARTED   36 
COMPLETED   29 
NOT COMPLETED   7 
Adverse Event                1 
Patiemt Non-compliance                1 
Evaluable for Toxicity Only                5 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
All Participants Rapid Hormonal Cycling as Treatment for Patients with Prostate Cancer

Baseline Measures
   All Participants 
Overall Participants Analyzed 
[Units: Participants]
 36 
Age 
[Units: Participants]
 
<=18 years   0 
Between 18 and 65 years   16 
>=65 years   20 
Gender 
[Units: Participants]
 
Female   0 
Male   36 


  Outcome Measures

1.  Primary:   Response   [ Time Frame: 6 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Dr. Howard Scher
Organization: Memorial Sloan Kettering Cancer Center
phone: 646-422-4323
e-mail: Scherh@mskcc.org



Responsible Party: Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT00586898     History of Changes
Other Study ID Numbers: 01-085
First Submitted: December 21, 2007
First Posted: January 7, 2008
Results First Submitted: December 16, 2015
Results First Posted: March 25, 2016
Last Update Posted: March 25, 2016